Argenica Therapeutics Banner Image

Argenica Therapeutics

  • Ticker AGN
    Exchange ASX More
  • Industry Biotechnology More
  • Sector Healthcare More
Argenica Therapeutics Logo Image
  • 1-10 Employees
  • Based in Nedlands, Australia
Argenica is developing and seeking to commercialise a “best in class” neuroprotective cationic arginine- rich peptide therapy to improve outcomes in stroke patients. Stroke is the leading cause of death and disability worldwide and the economic costs of treatment and post-stroke care are substantial. With current treatments, 20% of sufferers die and 50% are left permanently disabled. MoreoverMore, the burden of stroke is increasing with an aging population and the ongoing epidemics of cardiovascular disease, diabetes and obesity.
4.8 / 5.0 (136)

Argenica Therapeutics reports have an aggregate usefulness score of 4.8 based on 136 reviews.

Argenica Therapeutics

Most Recent Annual Report

Argenica Therapeutics
MOST RECENT 2023 Annual Report

Older/Archived Annual Reports

Argenica Therapeutics Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!